A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid Tumors

NCT03495323 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

DRUG: LY3300054
DRUG: Prexasertib

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]